Plain-English translation of NCT06750419 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new imaging scan called that uses a special radioactive tracer to help doctors identify whether an unclear kidney mass is a specific type of kidney cancer called clear cell renal cell carcinoma. The scan works by using girentuximab, a medication that attaches to cancer cells and helps them show up on the imaging. Researchers want to confirm that this scan is accurate and safe in Chinese patients who already have a planned surgery to remove or partially remove their kidney.
Many patients have unclear spots on their kidneys that doctors cannot easily identify as cancer or non-cancer without surgery. This medication aims to solve that problem by providing doctors with a clearer picture before surgery, which could help guide treatment decisions and potentially avoid unnecessary procedures.
You likely qualify if…
You likely don't qualify if…
You will visit the study center about 7 times over approximately 3 months. On your first visit, doctors will confirm your eligibility and do baseline tests. On Day 0, you will receive an injection of the medication through an IV. About 5 days later, you will have an abdominal PET/CT scan (a special imaging test that takes pictures of your kidney area). After the scan, your planned kidney surgery will happen within 90 days, and tissue samples from the surgery will be analyzed to see how accurate the scan was.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China